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Abstract
Background: The accuracy of 18F-fluorodeoxygluocose positron emission tomography/computed tomography
(PET/CT) in predicting immediate failure after radical chemoradiotherapy (CRT) for HNSCC is poorly characterized
at present. The purpose of this study was to examine PET/CT as a predictive and prognostic gauge of immediate
failure after CRT and determine the impact of these studies on clinical decision making in terms of salvage surgery.
Methods: Medical records of 78 consecutive patients receiving radical CRT for locally advanced HNSCC were
reviewed, analyzing PET/CTs done before and 3 months after CRT. Immediate failure was defined as residual
disease or locoregional and/or systemic relapse within 6 months after CRT.
Results: Maximum standard uptake value (SUV) of post CRT PET/CT (postSUVmax) was found optimal for predicting
immediate failure at a cutpoint of 4.4. Sensitivity, specificity, negative predictive value (NPV), and positive predictive
value (PPV) were 90.0 %, 83.8 %, 98.3 %, and 45.0 %, respectively. Of 78 patients studied, postSUVmax ≥4.4 prevailed
in 20 (25.6 %), with postSUVmax <4.4 in 58 (74.4 %). At postSUVmax ≥4.4 (vs. postSUVmax <4.4) OS was poorer by
comparison (3-year OS: 56.9 vs. 87.7 %; P = 0.005), as was progression-free survival (3-year PFS: 42.9 vs. 81.1 %;
P < 0.001). At postSUVmax ≥4.4, OS with and without immediate salvage surgery did not differ significantly (3-year OS:
60.0 vs. 55.6 %; Log-rank P = 0.913).
Conclusion: Post CRT PET/CT imaging has prognostic value in terms of OS and PFS and is useful in predicting
immediate therapeutic failure, given its high NPV. However, OS was not significantly altered by early salvage
surgery done on the basis of post CRT PET/CT findings.
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Background
More than a half million people are diagnosed with head
and neck squamous cell carcinoma (HNSCC) each year,
accounting for nearly 10 % of cancers worldwide [1].
Despite recent progress in treating this disease, a sub-
stantial number of patients experience locoregional and/
or systemic failure (LRSF) within the first 3 years of
definitive therapy [2, 3]. The prognosis with such failure is
poor, marked by median overall survival (OS) <1 year [4].
Hence, there is clinical need for more timely detection of
disease relapse or progression, enabling early intervention
while disease burden is low.
Functional imaging with 18F-fluorodeoxyglucose (FDG)
positron emission tomography/computed tomography
(PET/CT) after definitive chemoradiotherapy (CRT) has
been investigated as a useful means of detecting residual
disease or recurrences earlier [2, 3]. Furthermore, PET/
CT imaging has been contemplated as a source of prog-
nostic biomarkers in HNSCC after definitive CRT [5, 6].
Despite the cumulative corroborative data that exists, use
of PET/CT for this purpose remains contentious, primar-
ily due to the lack of prospective trials that address the
ramifications for patient management.
Salvage surgery is considered the most curative inter-
vention for residual or recurrent disease in the aftermath
of definitive CRT [7]. However, given the functional dis-
ability that generally results, selecting candidates appro-
priate for salvage surgery is often difficult. In addition,
indications for salvage surgery and the survival benefits
thereof are still anecdotal due to a limited body of
evidence.
In the course of this study, we evaluated the predictive
and prognostic value of PET/CT imaging in the context
of immediate locoregional and/or systemic failure (iLRSF)
after radical CRT, assessing any related impact on clinical
outcomes of salvage surgery.
Methods
Study population
Patients treated at Seoul National University Hospital
(SNUH) between January, 2005 and January, 2013 for
locally advanced HNSCC (LA-HNSCC) were reviewed
retrospectively. A total of 78 patients whose treatment
responses were assessed by whole-body FDG PET/CT
scans before and after definitive therapy qualified for
study. Primary sites were oropharynx, hypopharynx, lar-
ynx, oral cavity, or nasal cavity. Biopsy-proven squamous
carcinomas of unknown origin in cervical lymph nodes
were presumed to be head and neck cancers and were
included. Patients having more than one measurable
lesion according to the Response Evaluation Criteria
in Solid Tumors (RECIST) Criteria v1.1 were also ad-
missible; and Eastern Cooperative Oncology Group
performance status (ECOG PS) 0–2 was required [8].
Staging was stipulated by the American Joint Committee
on Cancer (7th edition).
Treatment
Modality of radical CRT was decided through multidis-
ciplinary approach by the SNUH Head and Neck Cancer
Team. Bulky nodal status, higher T- or N-stage, and the
possibility of organ preservation after induction chemother-
apy influenced the decision-making process [9]. Patients of
the IC/CRT group received induction chemotherapy (IC)
upfront for two or three cycles every 3 weeks, followed
by definitive CRT. Patients of the CRT group were
given definitive CRT directly, without IC. IC regimens
included docetaxel, cisplatin, 5-fluorouracil, or cetuxi-
mab. Radiotherapy was delivered daily on 5 days a week
using 3-dimensional conformal radiotherapy (3D-CRT)
or intensity-modulated radiotherapy (IMRT) with cisplatin
or cetuximab. On planning computed tomography images,
gross tumor volumes at primary sites and metastatic
nodes and clinical target volumes for occult tumor spreads
were delineated. Gross tumor volumes included any docu-
mented tumors in primary sites and metastatic lymph
nodes with a least margin of 5 mm. Selection of cervical
lymph nodal stations in clinical target volumes was
decided with consideration of clinical stages, location of
primary tumors and physician’s discretion. 3D-CRT was
delivered using conventional fractionation with a 1.8-Gy
daily dose: gross tumor received 70 Gy or higher, while
high-risk and low-risk regional nodal stations received
60 Gy and 45 Gy, respectively. For IMRT, simultaneous
integrated boost technique was used to deliver differential
daily doses to various target volumes in 30 daily fractions:
67.5 Gy to gross tumor, 54 Gy and 48 Gy to high-risk and
low-risk clinical target volumes, respectively. To account
for set up errors, clinical target volumes were expanded by
3 mm to generate planning target volumes.
For second curative attempts after definitive CRT, the
multidisciplinary team identified candidates for salvage
surgery based on follow-up CT, MRI, PET/CT, and/or
biopsy results of suspicious residual lesions. Technical
feasibility and preemptive medical conditions were
considered as well.
FDG PET/CT studies
Whole-body FDG PET/CT scans were acquired before
(baseline PET/CT) and 3.2 ± 1.1 months after definitive
therapy (post CRT PET/CT) for early metabolic response
evaluations. FDG PET/CT was done using dedicated
scanners (Gemini PET/CT: Philips Healthcare, Best,
The Netherlands; Biograph 40 or Biograph 64 PET/CT:
Siemens Healthcare, Munich, Germany). Patients fasted
for at least 6 h before FDG injection. FDG (5.18 MBq/kg)
was administered intravenously, and images were acquired
approximately 60 min after injection. A CT scan for
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attenuation correction and anatomic correlation was done
first (120 kVp, 50-160 mAs). Whole-body emission scans
were obtained from base of skull to proximal thigh for
2 min in recumbent position. PET images were recon-
structed using iterative algorithms (ordered-subset expect-
ation maximization) on 256 × 256 matrix.
Standard uptake values (SUVs) were calculated from
the amount of injected FDG activity, body weight, and
tissue uptake in the attenuation-corrected regional images
as follows: SUV = (activity/unit volume) / (injected dose/
body weight). For quantitative assessment of tumor FDG
uptake, a spherical volume of interest (VOI) was manually
drawn to include the highest radioactivity concentration
of tumor or regional lymph node, using an image analysis
software package (Syngo.via; Siemens Healthcare). Max-
imum SUV (SUVmax) was defined as the highest SUV
value within the VOI range of tumor or regional lymph
nodes.
Response evaluation
Complete physical examinations and all imaging studies,
including MRI or CT of head and neck and PET/CT
images were assessed, as well as any CT studies (chest,
abdomen) and brain MRI obtained as indicated by spe-
cific symptoms or clinical suspicions. In keeping with
our institutional protocol, baseline PET/CT was done in
all patients with HNSCC prior to initiation of definitive
therapy. To assess response of primary tumor to CRT,
CT of primary site and neck and/or MRI with contrast
were performed in combination with panendoscopy at
4–8 weeks after the end of CRT as recommended in Na-
tional Comprehensive Cancer Network (NCCN) guideline
[10]. Most of patients underwent post CRT PET/CT
3 months after completion of definitive CRT. In some
instances, post CRT PET/CT scans were done earlier or
later than 3 months, as dictated by clinical suspicions of
residual or recurrent disease. Follow-up imaging was
performed after two or three cycles of IC, at 4–8 weeks
after the end of CRT, and then every 3–6 months until
progression or death. Responses to treatment were evalu-
ated according to RECIST v1.1 [8]. Metabolic tumor re-
sponse was assessed according to the SUV measurement
criteria of European Organization for Research and Treat-
ment of Cancer [11]. The metabolic complete response
(mCR) was defined complete resolution of FDG uptake in
the tumor such that activity is less intense than the liver
and indistinguishable from surrounding background blood
pool levels.
Outcome measurement
iLRSF was defined as residual disease or locoregional
and/or systemic relapse within 6 months after CRT,
because in such case HNSCC was considered to be
platinum-refractory [12]. As primary outcome measures,
accuracy of post CRT PET/CT in predicting iLRSF and
prognostic value in terms of OS and progression-free
survival (PFS) were evaluated. LRSF beyond 6 months was
presumed independent of post CRT PET/CT findings. As
secondary objective, we evaluated the survival benefit of
salvage surgery performed on the basis of post CRT PET/
CT, measuring OS from date of diagnosis until death or
last follow-up visit (if censored). PFS was calculated from
the first day of initial IC or CCRT to the date of disease
progression (confirmed by imaging or biopsy), death, or
last follow-up visit (if censored).
Statistical analysis
The differences in clinicaopathologic characteristics
according to whether patients achieved mCR or not were
tested for significane using Mann-Whitney test for con-
tinuous variables and the chi-square test or Fisher’s exact
text for categorical variables. Of the various metabolic
parameters, optimal predictive indices and cutpoints were
obtained via Youden index [13]. Sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) were estimated. OS and PFS in all patients
and in various subgroups, namely those defined by pre-
dictive thresholds, were estimated through Kaplan-Meier
method. Between-group differences in OS and PFS were
compared using log-rank test. All reported P values
were two-sided, with statistical significance set at P < 0.05.
Above calculations relied on standard software (STATA
version 11; StataCorp LP, College Station, Texas, USA).
Ethical consideration
The study was approved by the Seoul National University
Hospital Institutional Review Board (SNUH IRB) (IRB
approval number: H-1307-051-504) and was conducted
in accordance with Declaration of Helsinki provisions.
Patient informed consent was waived from SNUH IRB
because of the retrospective design of the study.
Results
Patient characteristics
Demographic and clinical characteristics are summarized
in Table 1. Median patient age was 62 years (range: 24–79
years). Induction chemotherapy (IC) was administered to
a majority of patients (64.1 %). All subjects underwent
PET/CT imaging at baseline, prior to initiating therapy,
and after completion of CRT (median, 3.0 months; range:
0.9–6.0 months). Of the 78 patients studied, 10 (12.8 %)
experienced iLRSF, confirmed by histologic examination
of suspicious lesions (n = 5) or clinical and imaging
follow-up assessments (n = 5). There were locoregional
failures in 9 patients (11.5 %): local failure in 9 patients,
both local and regional failure in 4 patients. In the
remaining one patient (1.3 %), both locoregional failure
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Table 1 Patient characteristics
Characteristics Total (N = 78) Non-mCR (N = 37) mCR (N = 41) P-value
Age, median (range) 62 (24–79) 62 (24–76) 61 (42–79) 0.288
Sex, n (%)
Male 63 (80.8) 27 (73.0) 36 (87.8)
Female 15 (19.23) 10 (27.0) 5 (12.2) 0.097
ECOG PS, n (%)
0 19 (24.4) 8 (21.6) 11 (26.8)
1 58 (74.4) 28 (75.7) 30 (73.2)
2 1 (1.3) 1 (2.7) 0 (0.0) 0.601*
Location, n (%)
Oropharynx 47 (60.3) 19 (51.4) 28 (68.3)
Hypopharynx 19 (24.4) 11 (29.7) 8 (19.5)
Larynx 3 (3.9) 2 (5.4) 1 (2.4)
Oral cavity 5 (6.4) 4 (10.8) 1 (2.4)
Nasal cavity/PNS 1 (1.3) 0 (0.0) 1 (2.4)
Others 3 (3.9) 1 (2.7) 2 (4.9) 0.364*
Pathology, n (%)
Undifferentiated SCC 2 (2.6) 2 (5.4) 0 (0.0)
Poorly differentiated SCC 13 (16.7) 4 (10.8) 9 (22.0)
Moderately differentiated SCC 20 (25.6) 7 (18.9) 13 (31.7)
Well differentiated SCC 7 (9.0) 6 (16.2) 1 (2.4)
Nonkeratinizing carcinoma 1 (1.3) 1 (2.7) 18 (43.9)
Unknown/not specified SCC 35 (44.9) 17 (45.6) 0 (0.0) 0.058*
TNM Stage, n (%)
III 23 (29.5) 8 (21.6) 15 (36.6)
IVA 54 (69.2) 29 (78.4) 25 (61.0)
IVB 1 (1.3) 0 (0.0) 1 (2.4) 0.140*
IC, n (%) 50 (64.1) 25 (67.6) 25 (61.0)
FP 4 (5.1) 3 (8.1) 1 (2.4)
DFP 16 (20.5) 6 (16.2) 10 (24.4)
DP 26 (33.3) 14 (37.8) 12 (29.3)
DP + cetuximab 4 (5.1) 2 (5.4) 2 (4.9) 0.544
CRT regimen, n (%)
Cisplatin 71 (91.0) 33 (89.2) 38 (92.7)
Cetuximab 3 (3.9) 1 (2.7) 2 (4.9)
Cisplatin + cetuximab 3 (3.9) 2 (5.4) 1 (2.4)
Cisplatin + 5-FU 1 (1.3) 1 (2.7) 0 (0.0) 0.689*
Total radiation dose
> 60 Gy 80 (97.6) 38 (97.4) 42 (97.7)
≤ 60 Gy 2 (2.4) 1 (2.6) 1 (2.3) 1.000*
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and distant metastasis were documented at the time of
relapse.
Following CRT, 41 patients (52.6 %) qualified as mCR
by post CRT PET/CT, whereas the remaining 37 patients
(47.4 %) did not. However, clinicopathological charac-
teristics of the two groups such as sex, ECOG PS, pri-
mary tumor location, pathology, TNM stage, treatment
protocol, total radiation dose did not differ significantly.
Although 10 patients (27.0 %) who did not achieve
mCR experienced iLRSF, no patients achieving mCR
suffered iLRSF (Fisher’s exact test, P < 0.001). Immedi-
ate salvage surgery was limited to six patients (7.7 %),
none of whom achieved mCR.
Predictive value of post CRT PET/CT compared with CT,
MRI
Of the various metabolic parameters, SUVmax of post
CRT PET/CT (postSUVmax) best predicted iLRSF
(Additional file 1: Table S1). The highest Youden index of
0.738 for postSUVmax corresponded with a cutpoint of
4.4 (Additional file 2: Table S2). The area under the
receiver operating characteristic curve (AUROC) was
0.91 (95 % CI, 0.84–0.99) (Fig. 1). Of the 78 patients
studied, postSUVmax ≥4.4 was documented in 20 pa-
tients (25.6 %), 9 (45.0 %) of whom experienced iLRSF;
whereas in 58 patients (74.4 %) with postSUVmax <4.4,
only one patient (1.7 %) experienced iLRSF (P < 0.001)
(Fig. 2). Sensitivity, specificity, NPV, and PPV of postSUV-
max were 90.0, 83.8, 98.3, and 45.0 %, respectively
(Table 2).
For seventy five patients, CT of primary site and neck
and/or MRI with contrast were performed at median 6
(range 4–12) weeks after completion of CRT. Responses
to CRT were complete response (CR) in 30 (40.0 %) pa-
tients, partial response (PR) in 34 (45.3 %) patients, stable
disease (SD) in 7 (9.3 %) patients and progressive disease
(PD) in 4 (5.3 %) patients. Five of 64 patients who
achieved CR/PR experienced iLRSF, whereas among 11
patients who did not achieve CR or PR, 4 patients experi-
enced iLRSF (P = 0.023). Sensitivity, specificity, NPV and
PPV of post CT or MRI were 44.4, 89.4, 92.2 and 36.4 %,
respectively (Table 2).
Survival analysis
Median follow-up duration was 52.7 months (range:
24.5–123.0 months). At postSUVmax ≥4.4 (vs postSUV-
max <4.4), OS was poorer by comparison (HR = 4.25,
95 % CI: 1.54–11.74; P = 0.005). Three-year OS rate was
56.9 % (95 % CI, 30.1–76.3 %) in patients with postSUV-
max ≥4.4, as opposed to 87.7 % (95 % CI, 75.9–94.0 %) in
patients with postSUVmax <4.4 (Fig. 3a). Similarly, PFS
was worse in patients with postSUVmax ≥4.4 relative to
those with postSUVmax <4.4 (HR = 4.79, 95 % CI: 2.02–
11.32; P < 0.001). Three-year PFS rates were 42.9 % (95 %
CI, 20.4–63.6 %) at postSUVmax ≥4.4 and 81.1 % (95 %
CI, 67.5–89.5 %) at postSUVmax <4.4 (Fig. 3b).
Immediate salvage surgery was performed in five of 20
patients with postSUVmax ≥4.4, and one of 58 patients
with postSUVmax <4.4 (Fig. 2). OS with and without
immediate salvage surgery did not differ significantly at
postSUVmax ≥4.4 (3-year OS: 60.0 vs 55.6 %; Log-rank
P = 0.913) or at postSUVmax <4.4 (3-year OS: 100.0 vs
87.5 %, Log-rank P = 0.716) (Fig. 4).
Table 1 Patient characteristics (Continued)
Failure in six months, n (%) 10 (12.8) 10 (27.0) 0 (0.0) <0.001*
Locoregional failure alone 9 (11.5) 9 (24.3) 0 (0.0)
Systemic & locoregional failure 1 (1.3) 1 (2.7) 0 (0.0)
Immediate salvage op, n (%) 6 (7.7) 6 (16.2) 0 (0.0) 0.009*
Abbreviations: mCR metabolic complete response, IC induction chemotherapy, CRT concurrent chemoradiotherapy, ECOG PS Eastern Cooperative Oncology
Group performance status, SCC squamous cell carcinoma, FP 5-fluorouracil and cisplatin, DFP docetaxel, 5-fluorouracil and cisplatin, DP docetaxel and cisplatin,
5-FU 5-fluorouracil
*Fisher’s exact test
Fig. 1 Area under reciever operating characteristic curve (AUROC)
of postSUVmax predicting immediate locoregional and/or systemic
failure. Abbreviations: postSUVmax, maximum standarized uptake
value in PET/CT after definitive CRT
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Discussion
Our analysis indicates that postSUVmax has value in
predicting iLRSF after definitive CRT. High postSUVmax
corresponded with poor prognosis, but OS was not
significantly altered by early salvage surgery done on
the basis of post CRT PET/CT findings.
In patients with HNSCC, recurrence is the dominant
cause of treatment failure. Therefore post-treatment follow-
up is well integrated into the management of HNSCC.
Post-treatment PET/CT is now commonly used to gauge
patient response after definitive CRT [14, 15]. Conventional
imaging (including contrast-enhanced CT and MRI) has
limited ability to distinguish between radiation induced
inflammation or fibrosis and residual or recurrent diseases.
On the other hand, PET/CT has not only improved the
precision of initial staging but also yielded significantly
better results for the detection of recurrence of HNSCC
after CRT than CT/MRI [16]. The sensitivity, NPV and
PPV of postSUVmax in our analysis were superior to those
of post CT or MRI imaging when predicting iLRSF.
As discovered in previous studies, higher SUVmax
values on post CRT PET/CT images may predict local
recurrence and OS [17–20]. However, a decisive SUV
cutpoint, enabling residual cancer to be distinguished
from inflammation, has been lacking to date [21, 22].
Herein, we found that a postSUVmax cutpoint of 4.4
served well in predicting iLRSF. Furthermore, it was
apparent postSUVmax also held prognostic value. In
other words, OS and PFS at postSUVmax ≥4.4 (vs post-
SUVmax <4.4) were poorer by comparison. Within a 6-
month time frame after definitive CRT, postSUVmax
≥4.4 signals the likelihood of recurrent or progressive
disease. On the other hand, postSUVmax <4.4 is indica-
tive of inflammation in the aftermath of radiation or
chemotherapy.
Fig. 2 CONSORT flow of study population: Therapeutic responses in 82 patients with HNSCC were retropsectively analyzed via baseline and post
CRT PET/CT images. Six of 22 patients registering postSUVmax ≥4.4 underwent salvage surgery, compared with one of 60 patients at postSUVmax
<4.4. Distribution of patients experiencing iLRS is shown below by postSUVmax cutpoint (≥4.4 vs <4.4). Abbreviations: HNSCC, head &
neck squamous cell carcinoma; CRT, chemoradiotherapy; PET/CT, positron emission tomography/computed tomography; postSUVmax,
maximum standardized uptake value in PET/CT after definitive CRT; iLRSF, immediate locoregional and/or systemic failure
Table 2 Performance of postSUVmax (at 4.4 cutpoint) and post
CT or MRI in predicting immediate locoregional and/or systemic
therapeutic failure
Post PET/CT Post CT or MRI
Value (%) 95 % CI Value (%) 95 % CI
Sensitivity 90.0 55.5–99.7 44.4 13.7–78.8
Specificity 83.8 72.9–91.6 89.4 79.4–95.6
NPV 98.3 90.8–100.0 92.2 82.7–97.4
PPV 45.0 23.1–68.5 36.4 10.9–69.2
Abbreviations: postSUVmax maximum standardized uptake value in PET/CT
after definitive CRT, NPV negative predictive value, PPV positive predictive
value, CI confidence interval
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The PPV we determined for postSUVmax was rela-
tively low (45.0 %) yet compared favorably with the
19–58 % range reported by others [21, 23–25], and it
is thought that PPV may be a function of proper timing
[15]. According to Schöder et al., post CRT PET/CT
should not be performed for 10–12 weeks after treatment
ends [15, 22, 26]. At a lesser interval (<4-8 weeks), inflam-
matory changes related to radiation or chemotherapy
are apt to increase false-positive interpretations. Fur-
thermore, small-volume residual disease may escape
detection by PET/CT, potentially increasing the num-
ber of false-negative readings [27]. In our cohort, 39 pa-
tients (50.0 %) viewed as high-risk for immediate failure
underwent post CRT PET/CT before 3 months had
elapsed, which perhaps explains the relatively low PPV
of postSUVmax. Still, the true value of PET/CT imaging
in this context is the high NPV attached. We recorded a
remarkably high NPV (98.3 %) for postSUVmax, as did
several earlier retrospective studies [21, 22, 26], suggesting
that negative PET/CT scans are exceedingly reliable for
determining the absence of residual disease. In fact, this
strategy has helped reduced post CRT neck dissections by
up to 85 % in patients initially treated for bulky nodal
disease [28, 29].
If residual/recurrent disease is resectable, salvage
surgery is regarded as standard of care. Nonetheless,
Fig. 3 Kaplan-Meier plots of survival in LA-HNSCC patients by postSUVmax cutpoint (≥4.4 vs <4.4). OS (a) and PFS (b) were poorer in patients
with postSUVmax≥ 4.4 compared with those with postSUVmax < 4.4. Abbreviations: OS, overall survival; PFS, progression-free survival; HNSCC,
head & neck squamous cell carcinoma; postSUVmax, maximum standardized uptake value in PET/CT after definitive CRT
Fig. 4 Kaplan-Meier plots of OS with and without salvage surgery in LA-HNSCC patients. OS did not differ significantly at postSUVmax≥ 4.4 (a) or
at postSUVmax < 4.4 (b). Abbreviations: OS, overall survival; HNSCC, head & neck squamous cell carcinoma; postSUVmax, maximum standardized
uptake value in PET/CT after definitive CRT
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even recent advances in extirpative and reconstructive
surgical techniques have not diminished the inherent
controversies. Many aspects of such surgeries are still
of dubious benefit. Although studies by Bachar GY et al.
and Goodwin et al. maintain that salvage surgery controls
disease long-term [30, 31], other sources emphasize that
these procedures (especially laryngectomy) are associated
with high morbidity rates and poor overall or disease-
specific survival [32, 33]. Higher rates of complications
and impaired quality of life after salvage surgery have the
potential to overshadow any theoretical gains [7, 32, 33].
Proper clinical selection of candidate for salvage surgery is
therefore paramount. Our decision to perform salvage
surgery was subsequently guided by the risk of immediate
failure, based on post CRT PET/CT results. The rationale
was that patients at high risk of immediate failure would
benefit most. Immediate salvage surgery took place in 5
of 20 patients with postSUVmax ≥4.4, four of whom
eventually developed iLRSF. Unfortunately, no signifi-
cant survival benefit was demonstrated when comparing
3-year OS rates with and without aggressive surgical inter-
vention. This disappointing outcome need to be further
addressed.
Our study has a number of acknowledged limita-
tions, the first being its retrospective design. Although
a heterogenous patient population resulted, the multi-
disciplinary, individualized approach implemented by
our institutional head and neck cancer team helped
to minimize consequences. Additionally, the sample
size did not confer adequate statistical power, and our
index/cutpoint for predicting iLRSF may not be applicable
to other institutions where patient population, equipment,
and imaging protocols differ. As much as we hope our
findings may prove relevant in future research, this par-
ticular investigation was never expected to be conclusive.
Finally, recurrence or progression of disease in five pa-
tients was only confirmed clinically, via imaging diag-
nostics. This leaves some uncertainty surrounding the
potential for residual viable tumor. Of note, salvage
surgery, including neck dissection, is not done routinely at
our institution, so opportunities for histologic verification
are limited. Given that previous reports have shown a
relationship between metabolic and pathologic responses
[34, 35], we believe that follow-up clinical and imaging
data provide reasonable support here for a disease-free
state.
Conclusions
In patients with HNSCC, functional imaging with 18F-
fluorodeoxyglucose PET/CT after definitive CRT has
prognostic value in terms of OS and PFS and is useful in
predicting therapeutic response. Residual disease is effect-
ively excluded by virtue of a high NPV. Immediate salvage
surgery may also be withheld in patients achieving mCR
who show no abnormal uptake on post CRT PET/CT. In
our hands, however, OS was not significantly altered by
early salvage surgery done on the basis of post CRT PET/
CT findings. A more extensive prospective study is war-
ranted to decide if post CRT PET/CT is acceptable as the
sole or most decisive factor in managing these patients.
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